About this trial
The goal of the MYSSELF (Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers) study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in self-collected samples, such as first-void urine and vaginal samples, are linked to the presence of endometrial, ovarian, vulvar, or vaginal (pre-)cancer or to postmenopausal bleeding. Samples collected by clinicians from the cervix or vulva, as well as blood and tissue samples, will be used for comparison. The study will explore whether these markers could help improve earlier and less invasive detection of gynecological cancers in the future.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Individuals having female genital organs, regardless of their gender identity.
18 years old or older at the time of signing the informed consent form.
Diagnosed with either endometrial, ovarian, vulvar, or vaginal cancer irrespective of stage; diagnosed with one of their precursor lesions; or individuals with postmenopausal bleeding.
Has not started any form of cancer treatment prior to study enrolment.
Disqualifiers
Individuals that underwent hysterectomy or ovariectomy.
Pregnant individuals or 6 weeks post-partum.
Treatment for endometrial, ovarian, vulvar, or vaginal (pre-)cancer in the last 6 months before participation in the study.
Participating in another interventional clinical study (where, e.g., a medical device, drug, or vaccine is evaluated) at the same time as participating in this study. Participation in another observational or low-interventional clinical study at the same time is allowed.
Trial design
Single group
Treatments tested in this trial
Colli-Pee 20 mL device with UCM
DeviceParticipants will collect a first-void urine (the initial part of the urine stream) sample with the 20 mL Colli-Pee device prefilled with urine conservation medium (UCM, DNA Genotek, Canada). This sample can be taken at home the day before or the day of the planned consultation at the hospital or at the hospital itself.
Evalyn Brush
DeviceParticipants will collect a vaginal self-sample with the Evalyn Brush (Rovers Medical Devices, The Netherlands) at home the day before or the day of the planned consultation at the hospital or at the hospital itself.
Treatment groups
Trial outcomes
Primary outcomes
Number and overview of biomarkers associated with the presence of gynecological (pre-)cancers
The primary objective of this study is to determine the feasibility of detecting (epi)genetic biomarkers in participants with (pre-)cancer (endometrial, ovarian, vulvar, or vaginal cancer). This evaluation will be conducted using multiple sample types: self-samples (first-void urine and vaginal samples), clinician-collected cervical/vulvar samples, blood samples, and tissue samples.
Secondary outcomes
Comparison of the biomarkers in different sample types
The secondary objective is to compare the presence of biomarkers across different sample types (self-samples (first-void urine and vaginal samples), clinician-collected cervical/vulvar samples, blood samples, and tissue samples).
Association of biomarkers and presence of postmenopausal bleeding
The third objective is to explore the association of the identified biomarkers with clinical characteristics in individuals with postmenopausal bleeding, a symptom that can arise from a variety of conditions, including but not limited to endometrial cancer.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Universiteit Antwerpen
Lead sponsor
University Hospital, Antwerp
Collaborator